^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan Hycela (rituximab/hyaluronidase)

    i
    Other names: SC MabThera, rHuPH20/MabThera, rHuPH20/rituximab, hyaluronidase/rituxmab
    Company:
    Biogen, Halozyme, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    6d
    CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting | N=18 --> 40
    Enrollment closed • Enrollment change
    |
    Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)
    20d
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=422, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    1m
    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=5, Terminated, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Funding
    Trial completion date • Trial termination
    |
    cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    3ms
    ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov)
    P3, N=635, Active, not recruiting, Acerta Pharma BV | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)
    3ms
    CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)
    5ms
    A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Georgetown University | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan Hycela (rituximab/hyaluronidase)
    7ms
    Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov)
    P3, N=102, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    8ms
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Thomas Jefferson University | Trial completion date: Jun 2025 --> Apr 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase)
    9ms
    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=44 --> 5 | Trial completion date: Aug 2028 --> Nov 2026 | Trial primary completion date: Aug 2028 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    10ms
    A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Georgetown University | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan Hycela (rituximab/hyaluronidase)
    11ms
    Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, University of Washington | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Zynyz (retifanlimab-dlwr) • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    12ms
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Thomas Jefferson University | Recruiting --> Active, not recruiting | N=30 --> 4 | Trial completion date: Mar 2025 --> Jun 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase)